The Effect of Aspirin on the Platelet Activation in Maintain Hemodialysis Patients

Objective To investigate the effect of aspirin on the platelet activation in MHD patients.Methods The studied subjects were divided into 3 groups (Group A and group B include 10 patients respectively who are all maintain hemodialysis patients with recurrent native AVF failure. Group C includes 10 healthy volunteers as controls). Group A had taken orally aspirin 75mg/d for Smonths and group B hadn't. The consequence of the survival of the native AVF was observed, and the expression of platelet activation markers (CD62P,CD63,PAC-1) were measured by FCM. Results With the treatment of aspirin for 3 months, the level of activated platelet in group A is much lower than that of group B, but remains much higher than group C (CD62P: group A 2.63 ± 1.08,group B 5.21 ± 1.90,groupC 1.31 ± 0.88, PA-B0.002,PA-c0.01;CD63: group A 1.34 ± 0.53; group B 1.92 ± 0.88, group C 0. 77 ± 0.47, PA-B0.05, PA-C0.05; PAC-1: group A 1.35 ± 0.68, group B 2.13 ± 0.87, group C 0.81 ± 0.41,PA-B 0.05, PA-C0.05). Conclusion Aspirin can inhibit the platelet activation partly.